Fusion of Dual-targeting Peptides with MAP30 Promotes the Apoptosis of MDA-MB-231 Breast Cancer Cells
10.13865/j.cnki.cjbmb2024.12.1304
- VernacularTitle:双靶向肽与苦瓜抗病毒蛋白融合促进MDA-MB-231乳腺癌细胞凋亡
- Author:
Yi-Xuan YANG
1
;
Xin-Yi WANG
1
;
Wei-Wei CHEN
1
;
Li GAN
1
;
Yu SUN
1
;
Tong LIN
1
;
Wei-Chun ZHAO
1
;
Zhen-Hong ZHU
1
Author Information
1. 浙江中医药大学生命科学学院,杭州 310053
- Publication Type:Journal Article
- Keywords:
arginine-glycine-aspartic peptide(RGD);
epidermal growth factor receptor interference peptide(EGFRi);
momordica antiviral protein(MAP30);
MDA-MB-231 cell;
tumor targeting;
apoptosis
- From:
Chinese Journal of Biochemistry and Molecular Biology
2025;41(2):260-272
- CountryChina
- Language:Chinese
-
Abstract:
Momordica antiviral protein 30 kD(MAP30)is a type Ⅰ ribosome-inactivating protein(RIP)with antibacterial,anti-HIV and antitumor activities but lacks the ability to target tumor cells.To in-crease its tumor-targeting ability,the arginine-glycine-aspartic(RGD)peptide and the epidermal growth factor receptor interference(EGFRi)peptide were fused with MAP30,which was named ELRL-MAP30.The efficiency of targeted therapy for triple-negative breast cancer(TNBC)MDA-MB-231 cells,which lack the expression of estrogen receptor(ER),Progesterone receptor(PgR)and human epidermal growth factor receptor-2(HER2),is limited.In this study,we focus on exploring the effect and mecha-nism of ELRL-MAP30 on TNBC MDA-MB-231 cells.First,we discovered that ELRL-MAP30 significant-ly inhibited the migration and invasion of MDA-MB-231 cells and induced MDA-MB-231 cell apoptosis.Moreover,ELRL-MAP30 treatment resulted in a significant increase in Bax expression and a decrease in Bcl-2 expression.Furthermore,ELRL-MAP30 triggered apoptosis via the Fak/EGFR/Erk and Ilk/Akt signaling pathways.In addition,recombinant ELRL-MAP30 can inhibit chicken embryonic angiogenesis,and also inhibit the tube formation ability of human umbilical vein endothelial cells(HUVECs),indica-ting its potential therapeutic effects on tumor angiogenesis.Collectively,these results indicate that ELRL-MAP30 has significant tumor-targeting properties in MDA-MB-231 cancer cells and reveals potential ther-apeutic effects on angiogenesis.These findings indicate the potential role of ELRL-MAP30 in the targeted treatment of the TNBC cell line MDA-MB-231.
